Deltex Medical Group PLC Release and first sale of HD-ICG in France
September 21 2017 - 2:01AM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
21 September 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Release and first sale of HD-ICG in France
21 September 2017 - Deltex Medical Group plc (AIM: DEMG), the
global leader in oesophageal Doppler monitoring ("ODM") announces
the release and first sales of its new High Definition Impedance
Cardiography (HD-ICG) modality in France.
The Company released the French language version of the HD-ICG
module on its CardioQ-ODM+ haemodynamic monitoring platform earlier
this month and supported clinical demonstrations to key opinion
leaders in France. Following the success of these evaluations, the
Company's distributor in France has placed a small initial order,
purchasing two HD-ICG consoles for demonstration purposes.
HD-ICG provides a continuous indirect, non-invasive measurement
of central blood flow using disposable single patient sensor sets.
The sensors are connected to the Deltex CardioQ-ODM+ platform via a
small console which also provides power; values are displayed on
specially designed screens on the Deltex monitor. It is ideally
suited to awake patients in both critical care and surgery who do
not tolerate ODM probes.
The Company expects to make margins of around 35% to 40% on
sales to European distributors of both HD-ICG consoles and
subsequent disposable sensor sets.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"We are delighted to have made the first sales of our HD-ICG
module into France, which is, by volume of patients treated, our
largest export market. We plan to release this new module into
additional select overseas markets over the remainder of the
year."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments 0203 621 4120
(TPI) Ltd info@turnerpope.com
Ben Turner
James Pope
Financial Public Relations
IFC Advisory 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM is the only
technology to measure blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM which is proven
to reduce complications suffered by patients after surgery and save
hospitals the costs of treating those complications.
Deltex Medical's CardioQ-ODM+ platform also now provides
clinicians with two further advanced haemodynamic monitoring
technologies. High Definition Impedance Cardiography is an entirely
non-invasive monitoring technology which creates an electrical
field across the chest and measures the disruption to this field
when the heart pumps blood. Pulse Pressure Waveform Analysis uses
peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamically stable
patients.
Company goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Company's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Company aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Company to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,400 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable products.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALMMMTMBITTBR
(END) Dow Jones Newswires
September 21, 2017 02:01 ET (06:01 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024